Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NKTR | NEKTAR THERAPEUTICS | 2026-05-22 14:59:45 | 66.61 | -1.94 | -2.83 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NKTR | 0000906709 | NEKTAR THERAPEUTICS | US6402683063 | 5299005I24806IOIYE03 | 943134940 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 455 MISSION BAY BOULEVARD SOUTH | SAN FRANCISCO | CA | 94158 | UNITED STATES | US | 4154825300 | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158 | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158 | INHALE THERAPEUTIC SYSTEMS INC | Biopharmaceuticals | 1990 | — | 137 | http://nektar.com | 318,000,000 | 29,472,092 | 33,786,032 | Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. | 2026-05-21 16:46:23 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 318,000,000 | 92,000,000 | 40.708 | 28,687,963 | -157,415,625 | -84.5849 |
| 2024 | 226,000,000 | 117,000,000 | 107.3394 | 186,103,588 | 2,485,771 | 1.3538 |
| 2023 | 109,000,000 | -595,000,000 | -84.517 | 183,617,817 | -5,617,322 | -2.9684 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Howard W. Robin | President, Chief Executive Officer | 2025 | 1,106,282 | 0 | 942,081 | 1,106,282 | 115,774 | 6,256,954 |
| Mark A. Wilson | Chief Legal Officer | 2025 | 645,950 | 0 | 0 | 0 | 21,951 | 667,901 |
| Howard W. Robin | President, Chief Executive Officer | 2024 | 1,084,590 | 0 | 0 | 976,131 | 105,850 | 3,762,693 |
| Sandra Gardiner | Chief Financial Officer | 2024 | 0 | 0 | 0 | 0 | 460,850 | 460,850 |
| Mark A. Wilson | Chief Legal Officer | 2024 | 540,000 | 0 | 0 | 336,600 | 21,697 | 1,297,327 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 63 |
| 2024 | 61 |
| 2023 | 137 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 55,232,000 | 98,427,000 | 90,122,000 |
| Cost Of Revenue | 0 | 30,686,000 | 33,768,000 |
| Gross Profit | 55,232,000 | 67,741,000 | 56,354,000 |
| Research And Development Expenses | 117,330,000 | 120,908,000 | 114,162,000 |
| General And Administrative Expenses | 68,673,000 | 76,751,000 | 77,417,000 |
| Operating Expenses | 195,334,000 | 203,625,000 | 353,806,000 |
| Operating Income | -140,102,000 | -105,198,000 | -263,684,000 |
| Net Income | -164,076,000 | -118,961,000 | -276,056,000 |
| Earnings Per Share Basic | -9.73 | -0.58 | -1.45 |
| Earnings Per Share Diluted | -9.73 | -0.58 | -1.45 |
| Weighted Average Shares Outstanding Basic | 16,870,930 | 205,661,000 | 190,001,000 |
| Weighted Average Shares Outstanding Diluted | 16,870,930 | 205,661,000 | 190,001,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 15,116,000 | 44,252,000 | 35,277,000 |
| Marketable Securities Current | 230,636,000 | 210,974,000 | 268,339,000 |
| Accounts Receivable | 400,000 | 0 | 1,205,000 |
| Inventories | 0 | 0 | 16,101,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 20,514,000 | 6,066,000 | 9,779,000 |
| Total Assets Current | 266,266,000 | 261,292,000 | 330,701,000 |
| Marketable Securities Non Current | 0 | 13,869,000 | 25,825,000 |
| Property Plant And Equipment | 2,060,000 | 3,411,000 | 18,856,000 |
| Other Assets Non Current | 5,648,000 | 4,647,000 | 4,644,000 |
| Total Assets Non Current | 14,140,000 | 42,558,000 | 67,332,000 |
| Total Assets | 280,406,000 | 303,850,000 | 398,033,000 |
| Accounts Payable | 10,770,000 | 11,560,000 | 9,848,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 22,271,000 | 29,972,000 | 22,162,000 |
| Total Liabilities Current | 53,536,000 | 61,400,000 | 51,269,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 8,625,000 | 7,241,000 | 4,635,000 |
| Total Liabilities Non Current | 137,038,000 | 181,713,000 | 215,777,000 |
| Total Liabilities | 190,574,000 | 243,113,000 | 267,046,000 |
| Common Stock | 2,000 | 19,000 | 19,000 |
| Retained Earnings | -3,760,286,000 | -3,596,210,000 | -3,477,249,000 |
| Accumulated Other Comprehensive Income | 17,000 | 61,000 | 80,000 |
| Total Shareholders Equity | 89,832,000 | 60,737,000 | 130,987,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,026,000 | 4,391,000 | 1,634,000 |
| Share Based Compensation Expense | 864,000 | 118,000 | 30,000 |
| Other Non Cash Income Expense | — | 0 | -1,300,000 |
| Change In Accounts Receivable | 0 | 3,045,000 | -4,776,000 |
| Change In Inventories | 0 | -497,000 | -699,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 15,449,000 | 4,187,000 | -3,583,000 |
| Change In Accounts Payable | -625,000 | 2,668,000 | -2,884,000 |
| Change In Other Liabilities | — | — | -17,124,000 |
| Cash From Operating Activities | -208,511,000 | -175,709,000 | -192,606,000 |
| Purchases Of Marketable Securities | 285,012,000 | 261,709,000 | 511,699,000 |
| Sales Of Marketable Securities | 0 | 0 | 0 |
| Acquisition Of Property Plant And Equipment | 171,000 | 1,468,000 | 865,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,197,000 | 142,570,000 | 139,564,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 864,000 | 118,000 | 30,000 |
| Repurchase Of Common Stock | 0 | 3,000,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 180,566,000 | 42,118,000 | 30,000 |
| Change In Cash | -29,136,000 | 8,975,000 | -52,950,000 |
| Cash At End Of Period | 15,116,000 | 44,252,000 | 35,277,000 |
| Income Taxes Paid | -195,000 | 76,000 | 2,656,000 |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -9.73 | -0.58 | -1.45 |
| Price To Earnings Ratio | -4.3453 | -24.0505 | -5.8446 |
| Earnings Growth Rate | 1,577.5862 | -60 | -26.3959 |
| Price Earnings To Growth Ratio | -0.0028 | 0.4008 | 0.2214 |
| Book Value Per Share | 5.3247 | 0.2953 | 0.6894 |
| Price To Book Ratio | 7.9404 | 47.2336 | 12.2927 |
| Ebitda | -163,245,000 | -114,494,000 | -271,766,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -325,000 | -11,054,000 | -11,961,000 |
| Free Cash Flow | -208,186,000 | -164,655,000 | -180,645,000 |
| Return On Equity | -1.8265 | -1.9586 | -2.1075 |
| One Year Beta | 2.1153 | 1.9074 | 2.4611 |
| Three Year Beta | 2.1351 | 1.7164 | 1.5175 |
| Five Year Beta | 1.7118 | 1.187 | 1.1788 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer | 2026-05-19 | 199 | D | 20,975 |
| ROBIN HOWARD W | Director, President & CEO | 2026-05-19 | 444 | D | 75,045 |
| ROBIN HOWARD W | Director, President & CEO | 2026-02-18 | 423 | D | 75,489 |
| Zalevsky Jonathan | Chief R&D Officer | 2026-02-18 | 180 | D | 21,174 |
| Zalevsky Jonathan | Chief R&D Officer | 2026-01-20 | 3,867 | D | 21,354 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Western Wealth Management, LLC | 2026-03-31 | 14,318 | 199 | 71.9497 |
| Seven Fleet Capital Management LP | 2026-03-31 | 309,385 | 4,300 | 71.95 |
| Smartleaf Asset Management LLC | 2026-03-31 | 130 | 2 | 65 |
| Sofinnova Investments, Inc. | 2026-03-31 | 36,661,835 | 509,546 | 71.95 |
| Squarepoint Ops LLC | 2026-03-31 | 7,726,351 | 107,385 | 71.95 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| iSHARES TRUST | 2026-03-31 | iShares U.S. Pharmaceuticals ETF | IHE | 78,204 | 5,626,777.8 | 0.5623 |
| EMPOWER FUNDS, INC. | 2026-03-31 | Institutional Class | MXMSX | 8,646 | 622,079.71 | 0.2727 |
| EMPOWER FUNDS, INC. | 2026-03-31 | Investor Class | MXMTX | 8,646 | 622,079.71 | 0.2727 |
| RUSSELL INVESTMENT FUNDS | 2026-03-31 | U.S. Small Cap Equity Fund | RIFBX | 4,961 | 356,943.95 | 0.1716 |
| AMERICAN CENTURY ETF TRUST | 2026-02-28 | Avantis Total Equity Markets ETF | AVTM | 21 | 1,448.58 | 0.0002 |